Literature DB >> 16707842

Prostaglandin facilitates afferent nerve activity via EP1 receptors during urinary bladder inflammation in rats.

Makoto Ikeda1, Masahito Kawatani, Takayuki Maruyama, Hiroko Ishihama.   

Abstract

We examined the effects of loxoprofen, a cyclooxygenase inhibitor, and ONO-8711, an EP1-receptor antagonist, on afferent nerve activity during acetic acid (AA, 0.1% v/v)-induced inflammation of the rat urinary bladder. Distension stimulation was performed (vesical pressure of 30 cm H2O) for 2 min. The neuronal discharge was recorded from L6 dorsal root filaments. The discharge was observed just after the beginning of distension and increased gradually thereafter. When the vesical pressure returned to control value, the discharge diminished abruptly. AA infusion increased the total number of spikes to 198 +/- 38.8% of control values. AA infusion also produced asynchronous discharge in 39% of the animals. Loxoprofen administration (1 mg/kg, i.v.) reduced the number of spikes to 40.3 +/- 14.8% of control values. ONO-8711 administration (1 and 3 mg/kg, i.v.) reduced the number of spikes to 81.6 +/- 1.6% and 32.2 +/- 7.4% of control values, respectively. These data indicate that loxoprofen or EP1-receptor antagonist inhibit the inflammation-related neuronal activity. EP1 receptors in the peripheral afferent nerve terminal and/or urothelium may facilitate the primary afferent nerve activity, which elicits the inflammation-induced micturition reflex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707842     DOI: 10.2220/biomedres.27.49

Source DB:  PubMed          Journal:  Biomed Res        ISSN: 0388-6107            Impact factor:   1.203


  10 in total

1.  Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics.

Authors:  Kang Jun Cho; Hyo Sin Kim; Jun Sung Koh; Joon Chul Kim
Journal:  Int Urogynecol J       Date:  2012-06-21       Impact factor: 2.894

Review 2.  The role of prostanoids in urinary bladder physiology.

Authors:  Mohammad S Rahnama'i; Philip E V van Kerrebroeck; Stefan G de Wachter; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2012-03-13       Impact factor: 14.432

Review 3.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

Review 4.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

5.  The differential contractile responses to capsaicin and anandamide in muscle strips isolated from the rat urinary bladder.

Authors:  Chikashi Saitoh; Chika Kitada; Wataru Uchida; Michael B Chancellor; William C de Groat; Naoki Yoshimura
Journal:  Eur J Pharmacol       Date:  2007-06-05       Impact factor: 4.432

Review 6.  PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency.

Authors:  Ruida Hou; Ying Yu; Jianxiong Jiang
Journal:  Biochem Pharmacol       Date:  2020-12-09       Impact factor: 5.858

7.  Neurophysiological modeling of bladder afferent activity in the rat overactive bladder model.

Authors:  Mahipal Choudhary; Els van Asselt; Ron van Mastrigt; Francesco Clavica
Journal:  J Physiol Sci       Date:  2015-03-18       Impact factor: 2.781

Review 8.  Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction.

Authors:  Mohammad Sajjad Rahnama'i; Gommert A Van Koeveringe; Philip E Van Kerrebroeck
Journal:  Nephrourol Mon       Date:  2013-09-10

9.  The cardiovascular and gastrointestinal adverse effects of cyclooxygenase inhibitors seems to be a major concern that restricts their use in the treatment of urinary bladder dysfunction.

Authors:  Kajetan Juszczak; Tomasz Drewa
Journal:  Cent European J Urol       Date:  2015

Review 10.  Rationale for the use of prostaglandins and phosphodiesterase inhibitors in the treatment of functional bladder disorders.

Authors:  Mohammad Sajjad Rahnama'i; Gommert A Van Koeveringe; Philip E Van Kerrebroeck
Journal:  Nephrourol Mon       Date:  2013-11-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.